title: Surgery to cure the Zollinger-Ellison syndrome.
abstract: METHODS
  The role of surgery in patients with the Zollinger-Ellison syndrome is controversial. To determine the efficacy of surgery in patients with this syndrome, we followed 151 consecutive patients who underwent laparotomy between 1981 and 1998. Of these patients, 123 had sporadic gastrinomas and 28 had multiple endocrine neoplasia type 1 with an imaged tumor of at least 3 cm in diameter. Tumor-localization studies and functional localization studies were performed routinely. All patients underwent surgery according to a similar operative protocol, and all patients who had surgery after 1986 underwent duodenotomy.
  
  
  RESULTS
  The 151 patients underwent 180 exploratory operations. The mean (+/-SD) follow-up after the first operation was 8+/-4 years. Gastrinomas were found in 141 of the patients (93 percent), including all of the last 81 patients to undergo surgery. The tumors were located in the duodenum in 74 patients (49 percent) and in the pancreas in 36 patients (24 percent); however, primary tumors were found in lymph nodes in 17 patients (11 percent) and in another location in 13 patients (9 percent). The primary location was unknown in 24 patients (16 percent). Among the patients with sporadic gastrinomas, 34 percent were free of disease at 10 years, as compared with none of the patients with multiple endocrine neoplasia type 1. The overall 10-year survival rate was 94 percent.
  
  
  CONCLUSIONS
  All patients with the Zollinger-Ellison syndrome who do not have multiple endocrine neoplasia type 1 or metastatic disease should be offered surgical exploration for possible cure.
authors.affiliation: Department of Surgery, University of California, San Francisco, and the San Francisco Veterans Affairs Medical Center, USA.
authors.forename: J A
authors.initials: JA
authors.lastname: Norton
authors.forename: D L
authors.initials: DL
authors.lastname: Fraker
authors.forename: H R
authors.initials: HR
authors.lastname: Alexander
authors.forename: D J
authors.initials: DJ
authors.lastname: Venzon
authors.forename: J L
authors.initials: JL
authors.lastname: Doppman
authors.forename: J
authors.initials: J
authors.lastname: Serrano
authors.forename: S U
authors.initials: SU
authors.lastname: Goebel
authors.forename: P L
authors.initials: PL
authors.lastname: Peghini
authors.forename: P K
authors.initials: PK
authors.lastname: Roy
authors.forename: F
authors.initials: F
authors.lastname: Gibril
authors.forename: R T
authors.initials: RT
authors.lastname: Jensen
mesh_terms: D000328:Adult; D018572:Disease-Free Survival; D004379:Duodenal Neoplasms / Q000401:mortality / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D015408:Gastrinoma / Q000401:mortality / Q000601:surgery*; D006801:Humans; D008206:Lymphatic Diseases / Q000401:mortality / Q000601:surgery; D008297:Male; D008875:Middle Aged; D018761:Multiple Endocrine Neoplasia Type 1 / Q000401:mortality / Q000601:surgery*; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000601:surgery; D015996:Survival Rate; D015043:Zollinger-Ellison Syndrome / Q000401:mortality / Q000601:surgery*